GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE158403 Query DataSets for GSE158403
Status Public on Sep 24, 2020
Title PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Combining PD-L1 blockade with inhibition of oncogenic mitogen-activated protein kinase (MAPK) signaling may result in long-lasting responses in patients with advanced melanoma. This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigated safety, tolerability and preliminary efficacy of durvalumab (anti–PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for patients with BRAF-mutated melanoma (cohort A, n=26), or durvalumab and trametinib given concomitantly (cohort B, n=20) or sequentially (cohort C, n=22) for patients with BRAF-wild type melanoma. Adverse events and treatment discontinuation rates were more common than previously reported for these agents given as monotherapy. Objective responses were observed in 69.2% (cohort A), 20.0% (cohort B) and 31.8% (cohort C) of patients, with evidence of improved tumor immune infiltration and durable responses in a subset of patients with available biopsy samples. In conclusion, combined MAPK inhibition and anti–PD-L1 therapy may provide treatment options for patients with advanced melanoma.
Overall design Melanoma biopsy mRNA profiles at baseline and following MAPKi/PD-1 blockade treatment.
Contributor(s) Ribas A, Campbell KM
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Sep 23, 2020
Last update date Sep 24, 2020
Contact name Antoni Ribas
Phone (310) 206-3928
Organization name University of California, Los Angeles
Department Medicine, HemOnc Division
Street address 9-954 Factor Bldg
City Los Angeles
State/province CA
ZIP/Postal code 90095-1678
Country USA
Platforms (1)
GPL16791 Illumina HiSeq 2500 (Homo sapiens)
Samples (95)
GSM4799042 AF241866-3
GSM4799043 AF241881-6
GSM4799044 AF308488-6
BioProject PRJNA665163
SRA SRP285080

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE158403_FPKM_matrix.txt.gz 3.0 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap